The price of Vaxcyte Inc. (NASDAQ:PCVX) shares last traded on Wall Street rose 0.69% to $41.14.
Based on available information, 7 analysts follow Vaxcyte Inc. (NASDAQ:PCVX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $70.00 and a low of $56.00, we find $63.00. Given the previous closing price of $40.86, this indicates a potential upside of 54.19 percent. PCVX stock price is now -7.66% away from the 50-day moving average and 23.35% away from the 200-day moving average. The market capitalization of the company currently stands at $3.21B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Among analysts, 0 rate the stock a hold while 7 rate it a buy. Brokers who have rated the stock have averaged $62.43 as their price target over the next twelve months.
With the price target enhanced from $52 to $58, Needham maintained Buy rating for Vaxcyte Inc. (NASDAQ: PCVX). On December 15, 2022, Guggenheim recently initiated its ‘Buy’ rating on the stock quoting a target price of $66, while ‘BTIG Research’ rates the stock as ‘Buy’.
In other news, Lukatch Heath, Director sold 315 shares of the company’s stock on Jan 10. The stock was sold for $14,526 at an average price of $46.12. Upon completion of the transaction, the Director now directly owns 3,125 shares in the company, valued at $0.13 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 12, Director Lukatch Heath sold 335 shares of the business’s stock. A total of $14,717 was realized by selling the stock at an average price of $43.93. This leaves the insider owning 3,125 shares of the company worth $0.13 million. Insiders disposed of 309,318 shares of company stock worth roughly $12.73 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PCVX stock. A new stake in Vaxcyte Inc. shares was purchased by JENNISON ASSOCIATES LLC during the first quarter worth $58,501,000. BRAIDWELL LP invested $56,044,000 in shares of PCVX during the first quarter. In the first quarter, PERCEPTIVE ADVISORS LLC acquired a new stake in Vaxcyte Inc. valued at approximately $48,134,000. D. E. SHAW & CO., INC. acquired a new stake in PCVX for approximately $40,001,000. FRED ALGER MANAGEMENT, LLC purchased a new stake in PCVX valued at around $36,092,000 in the second quarter. In total, there are 231 active investors with 74.10% ownership of the company’s stock.
A candlestick chart of Vaxcyte Inc. (NASDAQ: PCVX) showed a price of $40.82 on Wednesday morning. During the past 12 months, Vaxcyte Inc. has had a low of $17.44 and a high of $49.31. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 23.30, and a quick ratio of 23.30. The fifty day moving average price for PCVX is $44.55 and a two-hundred day moving average price translates $33.35 for the stock.
The latest earnings results from Vaxcyte Inc. (NASDAQ: PCVX) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$0.93, missing analysts’ expectations of -$0.84 by -0.09. This compares to -$0.54 EPS in the same period last year. The company reported revenue of $86.57 million for the quarter, compared to $29.85 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 190.06 percent.
Vaxcyte Inc.(PCVX) Company Profile
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
